长效生长抑素类似物对神经内分泌肿瘤患者68Ga-DOTATATE摄取的影响
该回顾性研究纳入165例神经内分泌肿瘤患者的192次68Ga-DOTATATE PET/CT,比较检查前3个月内使用与未使用长效生长抑素类似物(SSA)者的SUVmax肿瘤/肝脏比值(TLR)。使用SSA者中位SUVmax TLR显著更高(4.7 vs 3.2,P<0.001),SSA使用是SUVmax TLR≥8.1的独立预测因素(OR 2.91,95%CI 1.26-6.72,P=0.012)。作者认为较高的SSA浓度对肿瘤病灶68Ga-DOTATATE摄取无负面影响。
要点
- 使用SSA者中位SUVmax TLR为4.7,未使用者为3.2,前者显著更高(P<0.001)。
- SSA使用是SUVmax TLR≥8.1的独立预测因素(OR 2.91,95%CI 1.26-6.72,P=0.012)。
- 作者认为较高SSA浓度对肿瘤病灶68Ga-DOTATATE摄取无负面影响。
核心结论
- 作者认为较高的SSA浓度对肿瘤病灶68Ga-DOTATATE摄取无负面影响,且仅SSA使用与SUVmax TLR≥8.1相关。
- 作者指出其结果与既往研究一致,并符合近期指南中相对近期使用SSA不需要延迟68Ga-DOTATATE PET/CT显像的建议。
研究设计与样本
- 回顾性研究,收集并回顾165例神经内分泌肿瘤患者的192次68Ga-DOTATATE PET/CT扫描。
- 按PET/CT前3个月内是否使用SSA(奥曲肽或兰瑞肽)分为无SSA组(n=115)和有SSA组(n=77)。
- 采用最大似然混合模型分析SSA对SUVmax值的影响,并用多因素logistic回归识别高SUVmax TLR的独立预测因素。
主要发现
- 有SSA组中位SUVmax TLR为4.7(IQR 3.1-7.7),无SSA组为3.2(IQR 2.0-5.4),有SSA组显著更高(P<0.001)。
- 多因素logistic回归显示SSA使用是SUVmax TLR≥8.1的独立预测因素(OR 2.91,95%CI 1.26-6.72,P=0.012)。
关键数值与推荐
- 原文引用:SUVmax TLR≥8.1与接受SSA治疗的NET患者无进展生存期延长相关。
- 原文引用:多个指南建议在每月长效SSA给药前进行PET/CT以避免理论上的相互作用。
- 原文引用:近期发表的指南建议相对近期使用SSA不需要延迟68Ga-DOTATATE PET/CT显像。
临床怎么用
- 作者结论提示相对近期使用SSA不需要延迟68Ga-DOTATATE PET/CT显像,与近期指南建议一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A high SUV max tumor-to-liver ratio (TLR) of 68 Ga-DOTATATE can be used to select patients with neuroendocrine tumors (NETs) for peptide receptor radionuclide therapy (PRRT). In addition, an SUV max TLR ≥ 8.1 is associated with increased progression-free survival in NET patients treated with somatostatin analogs (SSAs). To avoid a theoretical interaction, several guidelines recommend performing PET/CT just before the monthly administration of long-acting SSAs. We aimed to investigate the effect of SSA on the SUV max of 68 Ga-DOTATATE in patients with NET and to identify independent predictors for high SUV max TLR. PATIENTS AND METHODS: For this retrospective study, 192 68 Ga-DOTATATE PET/CT scans of 165 patients without (n = 115) and with (n = 77) SSA (octreotide or lanreotide) in the 3 months before PET/CT were collected and reviewed. The effect of SSA on SUV max values was analyzed by a maximum likelihood mixed model. RESULTS: Patients with SSA had a significantly higher median SUV max TLR than patients without SSA (4.7 [IQR], 3.1-7.7) versus 3.2 [IQR, 2.0-5.4]; P < 0.001). Multivariable logistic regression analysis showed that SSA use was an independent predictor for SUV max TLR ≥ 8.1 (odds ratio, 2.91; 95% confidence interval, 1.26-6.72; P = 0.012). CONCLUSIONS: Our data suggest that higher SSA concentrations do not have a negative effect on 68 Ga-DOTATATE uptake in tumor lesions. In addition, we found that only SSA use was associated with SUV max TLR ≥ 8.1. Our results are consistent with previously conducted studies and in line with the recently published guideline that suggests that the relatively recent use of SSA does not necessitate any delay in 68 Ga-DOTATATE PET/CT imaging.
引用
- Chahid Y, Hashimi K, van de Garde EMW, et al. The Influence of Long-Acting Somatostatin Analogs on 68 Ga-DOTATATE Uptake in Patients With Neuroendocrine Tumors. Clin Nucl Med. 2023. PMID: 37486312. doi:10.1097/RLU.0000000000004776
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。